Using fluvoxamine to treat COVID-19 patients reduces the need for prolonged hospitalization, trial shows

By | October 28, 2021
The results of a new randomized clinical trial, published in The Lancet Global Health, have demonstrated that using fluvoxamine to treat high-risk outpatients with early-diagnosed COVID-19 reduced the need for prolonged observation in an emergency setting or hospitalization, compared to a control group who received a placebo.